title: [Study on preparation and characterization of resveratrol solid lipid nanoparticles and its anticancer effects in vitro].
abstract: OBJECTIVE
  To prepare resveratrol solid lipid nanoparticles (Res-SLN) and investigate its physical and chemical speciality and anticancer effects in vitro.
  
  
  METHODS
  Res-SLN was prepared by the solvent emulsification-evaporation method. Its morphology, particle size and zata potential were examined by transmission electron microscope and laser granularity equipment. Its entrapment efficiency, drug loading, release concentration were determined by HPLC. Its anticancer effect of Res-SLN in vitro were studied by MTT.
  
  
  RESULTS
  Res-SLN assumed spherical shape. Its distribution of diameter was even with average particle size of 96. 7 nm, zata potential was--16.3mV, drug loading was (7.95 +/- 0.21)%, entrapment efficiency was (91.34 +/- 0.18)%; Res-SLN could retard drug release in vitro and its cytotoxicity was significantly higher than that of oridonin solution against HepG2 cells.
  
  
  CONCLUSIONS
  Res-SLN has high entrapment efficiency and drug loading, uniform particle size, and can retard drug release in vitro and enhance anticancer effect.
authors.affiliation: Huaiyin Institute of Technology, Key Laboratory for Attapulgite and Applied Technology of Jiangsu Province, Huaian 223003, China.
authors.forename: Qiang-Hua
authors.initials: QH
authors.lastname: Zhang
authors.forename: Qing-Ping
authors.initials: QP
authors.lastname: Xiong
authors.forename: Ying-Ying
authors.initials: YY
authors.lastname: Shi
authors.forename: Dan-Yan
authors.initials: DY
authors.lastname: Zhang
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D049109:Cell Proliferation / Q000187:drug effects; D003692:Delayed-Action Preparations; D004337:Drug Carriers / Q000737:chemistry*; D004339:Drug Compounding / Q000379:methods; D004355:Drug Stability; D005989:Glycerides / Q000737:chemistry; D056945:Hep G2 Cells; D006801:Humans; D008055:Lipids / Q000737:chemistry*; D053758:Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure; D010316:Particle Size; D010743:Phospholipids / Q000737:chemistry; D020442:Poloxamer / Q000737:chemistry; D000077185:Resveratrol; D013267:Stilbenes / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics*; D013499:Surface Properties
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D005989:Glycerides; D008055:Lipids; D010743:Phospholipids; D013267:Stilbenes; D020442:Poloxamer; C048159:glyceryl monostearate; D000077185:Resveratrol